Published in Cancers (Basel) on December 13, 2013
Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. Cancers (Basel) (2014) 0.76
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A (1998) 4.76
Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 4.51
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res (2002) 3.54
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol (1994) 2.84
Circulating epithelial cells in patients with benign colon diseases. Clin Chem (2011) 2.57
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A (1998) 2.32
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol (1996) 2.08
Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol (1996) 1.90
Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol (2011) 1.79
Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71
Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res (2008) 1.67
Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem (2011) 1.60
Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci (2006) 1.55
Challenges and opportunities for small molecule aptamer development. J Nucleic Acids (2012) 1.48
Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer (2000) 1.35
Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem (2011) 1.30
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29
EpCAM: structure and function in health and disease. Biochim Biophys Acta (2013) 1.27
RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci (2011) 1.19
High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules (2011) 1.16
Engineered protein scaffolds for molecular recognition. J Mol Recognit (2000) 1.15
Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope. J Mol Biol (2007) 1.13
Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol (2006) 1.06
DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol (2011) 0.97
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int (2010) 0.96
Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia. Clin Cancer Res (2007) 0.88
Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Mod Pathol (2010) 0.85
Fine tuning of the specificity of an anti-progesterone antibody by first and second sphere residue engineering. J Biol Chem (2005) 0.84
High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain. PLoS One (2012) 0.82